Sibeprenlimab-szsi for Primary IgA Nephropathy: A New Drug Review

Sibeprenlimab-szsi (Voyxact; Otsuka) is a first-in-class monoclonal antibody that inhibits A proliferation-inducing ligand (APRIL), an upstream mediator of pathogenic immunoglobulin A (IgA) production. In November 2025, sibeprenlimab received FDA accelerated approval to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk for disease progression. Clinical trial data demonstrate substantial reductions in proteinuria when added to optimized supportive care. However, long-term effects on kidney function decline remain unconfirmed. Pharmacists should understand sibeprenlimab’s mechanism, safety considerations, and emerging role within an increasingly complex IgAN treatment landscape.^1-4

Indication

Sibeprenlimab is FDA-approved for the reduction of proteinuria in adults with primary IgA nephropathy who are at risk for disease progression. Approval was based on interim phase 3 data demonstrating a clinically meaningful reduction in proteinuria compared with placebo. Continued approval is contingent upon evaluating long-term kidney outcomes.¹

IgA Nephropathy and Current Management

Primary IgAN is the most common primary glomerulonephritis worldwide and a major cause of chronic kidney disease. The disease is characterized by mesangial deposition of immune complexes containing galactose-deficient IgA1 (Gd-IgA1), triggering inflammation, fibrosis, and progressive loss of kidney function.^5-7

Optimized supportive care remains the foundation of IgAN management and includes blood pressure control, renin–angiotensin system blockade, dietary sodium restriction, and use of sodium–glucose cotransporter-2 (SGLT2) inhibitors when appropriate. Despite these measures, many patients experience persistent proteinuria, which is strongly associated with disease progression and has become a key surrogate end point in clinical trials.²

In recent years, multiple disease-specific therapies have been approved, reflecting a shift toward targeted treatment strategies. These agents act on distinct pathogenic pathways, including mucosal immunity, endothelin signaling, complement activation, and B-cell-mediated immunologic processes.²

Mechanism of Action

Sibeprenlimab is a humanized IgG2 monoclonal antibody that selectively binds soluble APRIL, a cytokine involved in B-cell survival and immunoglobulin class switching. APRIL signaling through BCMA and TACI receptors contributes to overproduction of aberrantly glycosylated IgA1, a central pathogenic factor in IgAN.¹

By neutralizing APRIL, sibeprenlimab reduces production of Gd-IgA1 and downstream immune complex formation. This upstream immunologic mechanism differentiates sibeprenlimab from therapies that primarily target downstream inflammation or glomerular hemodynamics.¹

Pharmacodynamics

Treatment with sibeprenlimab results in rapid and sustained suppression of circulating APRIL levels. In clinical studies, APRIL suppression exceeded 90% by week 4 and was maintained with monthly dosing.⁶

Mean reductions observed over 48 weeks included substantial decreases in Gd-IgA1 and total IgA, along with reductions in IgM and IgG. These effects confirm target engagement but have implications for infection risk.⁶

Pharmacokinetics

Sibeprenlimab has an absolute subcutaneous bioavailability of approximately 92%, with peak concentrations occurring approximately 8 days after administration. Steady-state concentrations are achieved by approximately 20 weeks with every-4-week dosing. The terminal half-life is approximately 9 days.⁶

Population pharmacokinetic analyses indicate no clinically meaningful differences based on age, sex, race, or mild-to-moderate renal impairment. Dedicated studies in severe renal or hepatic impairment have not been conducted.⁶

Clinical Efficacy

Phase 2 Data

In the phase 2 ENVISION trial (NCT04287985), sibeprenlimab demonstrated statistically significant reductions in proteinuria compared with placebo over 12 months in patients with primary IgAN. These findings supported further clinical development and validated APRIL as a therapeutic target.⁴

Phase 3 Data

The ongoing phase 3 VISIONARY trial (NCT05248646) is a randomized, double-blind, placebo-controlled study enrolling adults with biopsy-confirmed primary IgAN and persistent proteinuria despite optimized supportive care.^3,8

An interim analysis of the first 320 patients reaching month 9 showed that sibeprenlimab produced an approximately 50% reduction in proteinuria, corresponding to a placebo-adjusted reduction of approximately 51%. Baseline characteristics reflected clinical practice, including widespread use of background renin–angiotensin system blockade and SGLT2 inhibitors.^3,8

Although proteinuria reduction is clinically meaningful and predictive of improved outcomes, the effect of sibeprenlimab on long-term kidney function decline has not yet been established. These data are required to confirm clinical benefit and support continued approval.^3,8

Contraindications, Warnings, and Precautions

Sibeprenlimab is contraindicated in patients with known serious hypersensitivity to the drug or its excipients.⁵ Treatment may increase the risk of immunosuppression and increase the risk of infections. Patients should be evaluated for active infections prior to initiation and monitored during therapy. Live vaccines should not be administered within 30 days before starting treatment or during therapy.⁵

Adverse Reactions

The most common adverse reactions reported in clinical trials included upper respiratory tract infections and injection-site reactions such as erythema. Rates of serious adverse events were generally similar between sibeprenlimab and placebo groups in interim analyses.⁵

Immunogenicity

Antidrug antibodies were detected in approximately one-third of treated patients. Neutralizing antibodies were associated with reduced drug exposure and numerically smaller reductions in proteinuria. The clinical implications of immunogenicity are not fully defined but may contribute to variability in treatment response.⁵

Dosing and Administration

Sibeprenlimab is supplied as a 400 mg/2 mL (200 mg/mL) single-dose prefilled syringe for subcutaneous injection. The recommended dosage is 400 mg injected subcutaneously once every 4 weeks. The injection may be administered by the patient or a caregiver following appropriate training. If a dose is missed, it should be administered as soon as possible, and the every-4-week schedule resumed.⁵

Sibeprenlimab’s Place in IgAN Therapy

Sibeprenlimab expands the range of disease-specific therapies available for IgAN and offers a novel upstream immunologic mechanism. It may be considered for patients with persistent proteinuria despite optimized supportive care who are candidates for immunomodulatory therapy and prefer a monthly injectable option.²

However, unlike some recently approved agents with demonstrated benefit in kidney function decline, sibeprenlimab currently lacks confirmed long-term outcome data. Until such data are available, careful patient selection and shared decision-making are essential.

The Role of the Pharmacist

Pharmacists are critical to the safe and effective use of sibeprenlimab. Key responsibilities include ensuring optimized background therapy, assessing vaccination status, educating patients on injection technique, monitoring for infection, and evaluating treatment response through serial proteinuria measurements.⁹

Conclusion

Sibeprenlimab is a first-in-class APRIL inhibitor approved for reduction of proteinuria in adults with primary IgAN. Clinical trial data demonstrate substantial proteinuria reductions when added to optimized supportive care. Although confirmatory data on long-term kidney outcomes are pending, sibeprenlimab represents a promising addition to the evolving IgAN treatment paradigm and underscores the growing role of targeted immunologic therapies.^1,3,4

References

1. Voyxact. Accessed March 11, 2026. https://www.voyxact.com/

2. IgA Nephropathy: Reviewing the Evidence on Current and Future Therapies. Cleveland Clinic. September 26, 2025. Accessed March 11, 2026. https://consultqd.clevelandclinic.org/iga-nephropathy-reviewing-the-evidence-on-current-and-future-therapies

3. Trial of sibeprenlimab in the treatment of A nephropathy (IgAN). ClinicalTrials.gov NCT05248646. Updated February 20, 2026. Accessed March 11, 2026. https://clinicaltrials.gov/study/NCT05248646

4. Mathur M, Barratt J, Chacko B, et al. A phase 2 trial of sibeprenlimab in patients with IgA nephropathy. N Engl J Med. 2024;390:20-31. doi:10.1056/NEJMoa2305635

5. Voyxact [prescribing information]. Otsuka America Pharmaceutical, Inc; November 2025. Accessed March 11, 2026. https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/761434s000lbl.pdf

6. Zhang X, Wang Y, Yarbrough J, et al. Safety, pharmacokinetics, and pharmacodynamics of subcutaneous sibeprenlimab in healthy participants. Clin Pharmacol Drug Dev. 2023;12(12):1211-1220. doi:10.1002/cpdd.1316

7. Perkovic V, Barratt J, Lafayette R, et al. Evaluating sibeprenlimab in IgA nephropathy – rationale and baseline data from the VISIONARY trial. Kid Int Rep. 2025;10(12):4207-4218. doi:10.1016/j.ekir.2025.09.031

8. Perkovic V, Trimarchi H, Tesar V, et al. Sibeprenlimab in IgA nephropathy — interim analysis of a phase 3 trial. N Engl J Med. 2025;394:635-646. doi:10.1056/NEJMoa2512133

9. The role of the pharmacist in public health. American Public Health Association. November 8, 2006. Accessed March 11, 2026. https://www.apha.org/policy-and-advocacy/public-health-policy-briefs/policy-database/2014/07/07/13/05/the-role-of-the-pharmacist-in-public-health